DiaMedica Therapeutics(DMAC) - 2023 Q4 - Annual Results

Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results Conference Call and Webcast March 20 at 8:00 AM Eastern Time / 7:00 AM Central Time ● ReMEDy2 Clinical Site Activation Commenced in December 2023 ● Strengthened Management Team with Lorianne Masuoka, M.D., as Chief Medical Officer ● $53 Million Cash with Runway to 2026 Minneapolis, Minnesota – March 19, 2024 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceut ...